Servier

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.

NEW YORK (GenomeWeb News) — Curie-Cancer, which leads Institut Curie's industry partnerships, and the French drug developer Servier have extended an ongoing partnership focused on breast cancer research for another three years, they said today.

MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.
The move triggered an undisclosed milestone payment to MiRagen.

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.

This story originally ran on Oct. 18
French biotech company Hybrigenics this week reported €1.85 million ($2.52 million) in first-half revenues from its proteomics services business, up eight percent from €1.71 million in the first half of 2010.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.